We are investigating how the amylin analogue Cagrilintide affects bone metabolism in participants. This study aims to learn more about its potential role in improving bone health.
Health conditions and diseases that the clinical trial is designed to study and treat.
This condition refers to women aged 50 to 70 who are post-menopausal and have a body mass index (BMI) of 30 or higher, indicating obesity. Post-menopause is defined by at least 12 months without a menstrual period and elevated hormone levels.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.